SME Times is powered by   
Search News
Just in:   • Escalation in Mideast may cause losses exceeding 2025 regional cumulative GDP: UN report  • GST collections rise 8.8 pc to Rs 2 lakh crore in March, clock 8.3 pc growth in FY26  • Auto sales boom in March, carmakers hit record highs  • Stock markets surge over 2 pc in early trade amid Iran war de-escalation hopes  • Quality control begins with careful vendor selection: Chaitik Shah 
Last updated: 01 Feb, 2017  

cadila.thumb.jpg Cadila Healthcare net profit declines 34.6 pc in Q3

cadila.jpg
   Top Stories
» Stock markets surge over 2 pc in early trade amid Iran war de-escalation hopes
» RBI postpones capital market exposure framework to July 1
» Industry hails Centre’s push on design, quality as ECMS gains pace
» Rs 11,200 crore Noida International Airport gives major connectivity boost, drives economic growth
» Crude oil drops over 5 pc this week, hovers above $100 amid global uncertainty
SME Times News Bureau | 01 Feb, 2017
Global pharmaceutical company Cadila Healthcare on Tuesday posted a 34.6 percent decline in its consolidated net profit to Rs 281.6 crore for the quarter ended December 31, 2016 as compared with Rs 430.5 crore in the year-ago period.

The company's consolidated total income from operations also dipped to Rs 2,363.8 crore during the quarter under review as compared with Rs 2,408.9 crore in a year-ago period.

On BSE, the stock settled at Rs 349.25, down 7.02 percent from the previous close.
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹91.35
89.65
UK Pound
₹125.3
₹121.3
Euro
₹108.5
₹104.85
Japanese Yen ₹58.65 ₹56.8
As on 19 Feb, 2026
  Daily Poll
What is the biggest war impact on MSMEs?
 Export Disruption
 Raw Material Spike
 Freight Cost Surge
 Payment Delays
 Currency Volatility
 All
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter